Investors

Financials & Filings

Filing date Form Description Filing Group View
PRE 14A

A preliminary proxy statement providing notification matters to be brought to a vote

Proxy Filings
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
4

Statement of changes in beneficial ownership of securities

3,4,5
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
144

Filed by "insiders" prior intended sale of restricted stock. Non-EDGAR filing

Other
S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.